NNC45-0781
目录号 : GC31565
NNC45-0781是一种组织选择性的雌激素(estrogen)部分激动剂。
Cas No.:207277-66-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Animal experiment: | Rats[1]Female Sprague-Dawley rats, 12 weeks of age, weighing approximately 250 g are used in these studies.The pharmacological properties of NNC45-0781 (NNC 45-0781) are studied through a series of in vivo experiments. Activity of orally administered NNC45-0781 (1,10, 50 and 100 nmol/g) on total serum cholesterol in the ovariectomized rat. |
References: [1]. Bury PS, et al. Synthesis and pharmacological evaluation of novel cis-3,4-diaryl-hydroxychromanes as high affinity partial agonists for the estrogen receptor. Bioorg Med Chem. 2002 Jan;10(1):125-45. | |
NNC45-0781 is a tissue-selective estrogen partial-agonist.
NNC45-0781 (NNC 45-0781) shows that it is a very promising tissue-selective estrogen agonist. Total serum cholesterol is significantly increased in the vehicle-treated group as compared to the sham animals. All of the animals receiving NNC45-0781 at doses of 10 nmol/g or higher, has significantly lower levels of total serum cholesterol as compared to the vehicle treated group[1].
[1]. Bury PS, et al. Synthesis and pharmacological evaluation of novel cis-3,4-diaryl-hydroxychromanes as high affinity partial agonists for the estrogen receptor. Bioorg Med Chem. 2002 Jan;10(1):125-45.
| Cas No. | 207277-66-5 | SDF | |
| Canonical SMILES | OC1=CC=C([C@@H](C2=CC=C(OCCN3CCCC3)C=C2)[C@@H](C4=CC=CC=C4)CO5)C5=C1 | ||
| 分子式 | C27H29NO3 | 分子量 | 415.52 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4066 mL | 12.0331 mL | 24.0662 mL |
| 5 mM | 0.4813 mL | 2.4066 mL | 4.8132 mL |
| 10 mM | 0.2407 mL | 1.2033 mL | 2.4066 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。